Keywords: uk, nice, oks, novartis, gleevec, first-line, gist

UK NICE OKs Novartis' Gleevec as first-line GIST management, also views epilepsy care

Article | 08 November 2004

Print This

The National Institute for Clinical Excellence has issued guidance for the National Health Service in England and Wales on the ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in